| mRNA |
dabrafenib |
CTRPv2 |
pan-cancer |
AAC |
0.32 |
5e-13 |
| mRNA |
IU1 |
CTRPv2 |
pan-cancer |
AAC |
0.22 |
2e-09 |
| mRNA |
PLX4720 |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
2e-08 |
| mRNA |
masitinib |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
4e-07 |
| mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
3e-06 |
| mRNA |
GDC-0879 |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
6e-06 |
| mRNA |
tacrolimus |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
1e-05 |
| mRNA |
GSK1120212 |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
2e-05 |
| mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
4e-05 |
| mRNA |
crizotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
7e-05 |